Trial Profile
A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 23 Nov 2021
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Granulocyte macrophage colony stimulating factor
- Indications Malignant melanoma
- Focus Therapeutic Use
- 22 Oct 2021 Status changed from recruiting to completed.
- 21 Nov 2016 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 21 Nov 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.